Outcomes in COVID-19 colchicine studies
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Deftereos (RCT) 77% 0.23 [0.03-1.97] death 1/55 4/50 Improvement, RR [CI] Treatment Control Lopes (DB RCT) 80% 0.20 [0.01-4.03] death 0/36 2/36 Brunetti (PSM) 73% 0.27 [0.08-0.89] death 3/33 11/33 Scarsi 85% 0.15 [0.06-0.37] death 122 (n) 140 (n) Salehzadeh (RCT) 23% 0.77 [0.66-0.90] hosp. time 50 (n) 50 (n) Pinzón 35% 0.65 [0.34-1.21] death 14/145 23/156 Sandhu 42% 0.58 [0.40-0.85] death 16/34 63/78 Rodriguez-Nava 6% 0.94 [0.61-1.47] death 16/52 85/261 Tardif (DB RCT) 44% 0.56 [0.19-1.67] death 5/2,235 9/2,253 Horby (RCT) -1% 1.01 [0.93-1.10] death 1,173/5,610 1,190/5,730 Gaitán-Dua.. (RCT) 19% 0.81 [0.48-1.35] death 22/153 28/161 CT1 Dorward (RCT) -30% 1.30 [0.42-3.84] hosp./death 6/156 4/133 Tau2 = 0.08; I2 = 73.9% Late treatment 31% 0.69 [0.54-0.88] 1,256/8,681 1,419/9,081 31% improvement All studies 31% 0.69 [0.54-0.88] 1,256/8,681 1,419/9,081 31% improvement 12 colchicine COVID-19 studies c19colchicine.com Oct 16, 2021 1 CT: study uses combined treatment Tau2 = 0.08; I2 = 73.9%; Z = 3.02 Effect extraction pre-specified Favors colchicine Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Deftereos (RCT) 77% 0.23 [0.03-1.97] death 1/55 4/50 Improvement, RR [CI] Treatment Control Lopes (DB RCT) 80% 0.20 [0.01-4.03] death 0/36 2/36 Brunetti (PSM) 73% 0.27 [0.08-0.89] death 3/33 11/33 Scarsi 85% 0.15 [0.06-0.37] death 122 (n) 140 (n) Salehzadeh (RCT) 23% 0.77 [0.66-0.90] hosp. time 50 (n) 50 (n) Pinzón 35% 0.65 [0.34-1.21] death 14/145 23/156 Sandhu 42% 0.58 [0.40-0.85] death 16/34 63/78 Tardif (DB RCT) 44% 0.56 [0.19-1.67] death 5/2,235 9/2,253 Horby (RCT) -1% 1.01 [0.93-1.10] death 1,173/5,610 1,190/5,730 Gaitán-Dua.. (RCT) 19% 0.81 [0.48-1.35] death 22/153 28/161 CT1 Dorward (RCT) -30% 1.30 [0.42-3.84] hosp./death 6/156 4/133 Tau2 = 0.08; I2 = 76.3% Late treatment 35% 0.65 [0.50-0.85] 1,240/8,629 1,334/8,820 35% improvement All studies 35% 0.65 [0.50-0.85] 1,240/8,629 1,334/8,820 35% improvement 11 colchicine COVID-19 studies after exclusions c19colchicine.com Oct 16, 2021 1 CT: study uses combined treatment Tau2 = 0.08; I2 = 76.3%; Z = 3.12 Effect extraction pre-specified Favors colchicine Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Deftereos (RCT) 77% 0.23 [0.03-1.97] 1/55 4/50 Improvement, RR [CI] Treatment Control Lopes (DB RCT) 80% 0.20 [0.01-4.03] 0/36 2/36 Brunetti (PSM) 73% 0.27 [0.08-0.89] 3/33 11/33 Scarsi 85% 0.15 [0.06-0.37] 122 (n) 140 (n) Pinzón 35% 0.65 [0.34-1.21] 14/145 23/156 Sandhu 42% 0.58 [0.40-0.85] 16/34 63/78 Rodriguez-Nava 6% 0.94 [0.61-1.47] 16/52 85/261 Tardif (DB RCT) 44% 0.56 [0.19-1.67] 5/2,235 9/2,253 Horby (RCT) -1% 1.01 [0.93-1.10] 1,173/5,610 1,190/5,730 Gaitán-Dua.. (RCT) 19% 0.81 [0.48-1.35] 22/153 28/161 CT1 Tau2 = 0.17; I2 = 74.5% Late treatment 40% 0.60 [0.42-0.86] 1,250/8,475 1,415/8,898 40% improvement All studies 40% 0.60 [0.42-0.86] 1,250/8,475 1,415/8,898 40% improvement 10 colchicine COVID-19 mortality results c19colchicine.com Oct 16, 2021 1 CT: study uses combined treatment Tau2 = 0.17; I2 = 74.5%; Z = 2.82 Favors colchicine Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lopes (DB RCT) 50% 0.50 [0.10-2.56] 2/36 4/36 Improvement, RR [CI] Treatment Control Gaitán-Dua.. (RCT) 1% 0.99 [0.56-1.74] 19/113 18/114 CT1 Tau2 = 0.00; I2 = 0.0% Late treatment 9% 0.91 [0.53-1.59] 21/149 22/150 9% improvement All studies 9% 0.91 [0.53-1.59] 21/149 22/150 9% improvement 2 colchicine COVID-19 ICU results c19colchicine.com Oct 16, 2021 1 CT: study uses combined treatment Tau2 = 0.00; I2 = 0.0%; Z = 0.31 Favors colchicine Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Salehzadeh (RCT) 23% 0.77 [0.66-0.90] hosp. time 50 (n) 50 (n) Improvement, RR [CI] Treatment Control Tardif (DB RCT) 20% 0.80 [0.61-1.03] hosp. 101/2,235 128/2,253 Tau2 = 0.00; I2 = 0.0% Late treatment 22% 0.78 [0.68-0.89] 101/2,285 128/2,303 22% improvement All studies 22% 0.78 [0.68-0.89] 101/2,285 128/2,303 22% improvement 2 colchicine COVID-19 hospitalization results c19colchicine.com Oct 16, 2021 Tau2 = 0.00; I2 = 0.0%; Z = 3.72 Favors colchicine Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Deftereos (RCT) 77% 0.23 [0.03-1.97] death 1/55 4/50 Improvement, RR [CI] Treatment Control Lopes (DB RCT) 80% 0.20 [0.01-4.03] death 0/36 2/36 Brunetti (PSM) 73% 0.27 [0.08-0.89] death 3/33 11/33 Scarsi 85% 0.15 [0.06-0.37] death 122 (n) 140 (n) Pinzón 35% 0.65 [0.34-1.21] death 14/145 23/156 Sandhu 42% 0.58 [0.40-0.85] death 16/34 63/78 Rodriguez-Nava 6% 0.94 [0.61-1.47] death 16/52 85/261 Tardif (DB RCT) 44% 0.56 [0.19-1.67] death 5/2,235 9/2,253 Horby (RCT) -1% 1.01 [0.93-1.10] death 1,173/5,610 1,190/5,730 Gaitán-Dua.. (RCT) 19% 0.81 [0.48-1.35] death 22/153 28/161 CT1 Dorward (RCT) -30% 1.30 [0.42-3.84] hosp./death 6/156 4/133 Tau2 = 0.16; I2 = 71.9% Late treatment 37% 0.63 [0.45-0.88] 1,256/8,631 1,419/9,031 37% improvement All studies 37% 0.63 [0.45-0.88] 1,256/8,631 1,419/9,031 37% improvement 11 colchicine COVID-19 serious outcomes c19colchicine.com Oct 16, 2021 1 CT: study uses combined treatment Tau2 = 0.16; I2 = 71.9%; Z = 2.69 Effect extraction pre-specified Favors colchicine Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Deftereos (RCT) 77% 0.23 [0.03-1.97] death 1/55 4/50 Improvement, RR [CI] Treatment Control Lopes (DB RCT) 80% 0.20 [0.01-4.03] death 0/36 2/36 Salehzadeh (RCT) 23% 0.77 [0.66-0.90] hosp. time 50 (n) 50 (n) Tardif (DB RCT) 44% 0.56 [0.19-1.67] death 5/2,235 9/2,253 Horby (RCT) -1% 1.01 [0.93-1.10] death 1,173/5,610 1,190/5,730 Gaitán-Dua.. (RCT) 19% 0.81 [0.48-1.35] death 22/153 28/161 CT1 Dorward (RCT) -30% 1.30 [0.42-3.84] hosp./death 6/156 4/133 Tau2 = 0.03; I2 = 57.1% Late treatment 14% 0.86 [0.69-1.06] 1,207/8,295 1,237/8,413 14% improvement All studies 14% 0.86 [0.69-1.06] 1,207/8,295 1,237/8,413 14% improvement 7 colchicine COVID-19 Randomized Controlled Trials c19colchicine.com Oct 16, 2021 1 CT: study uses combined treatment Tau2 = 0.03; I2 = 57.1%; Z = 1.40 Effect extraction pre-specified Favors colchicine Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Deftereos (RCT) 77% 0.23 [0.03-1.97] 1/55 4/50 Improvement, RR [CI] Treatment Control Lopes (DB RCT) 80% 0.20 [0.01-4.03] 0/36 2/36 Tardif (DB RCT) 44% 0.56 [0.19-1.67] 5/2,235 9/2,253 Horby (RCT) -1% 1.01 [0.93-1.10] 1,173/5,610 1,190/5,730 Gaitán-Dua.. (RCT) 19% 0.81 [0.48-1.35] 22/153 28/161 CT1 Tau2 = 0.02; I2 = 15.2% Late treatment 8% 0.92 [0.72-1.17] 1,201/8,089 1,233/8,230 8% improvement All studies 8% 0.92 [0.72-1.17] 1,201/8,089 1,233/8,230 8% improvement 5 colchicine COVID-19 RCT mortality results c19colchicine.com Oct 16, 2021 1 CT: study uses combined treatment Tau2 = 0.02; I2 = 15.2%; Z = 0.69 Favors colchicine Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Deftereos (RCT) 77% 0.23 [0.03-1.97] death 1/55 4/50 Improvement, RR [CI] Treatment Control Lopes (DB RCT) 80% 0.20 [0.01-4.03] death 0/36 2/36 Brunetti (PSM) 73% 0.27 [0.08-0.89] death 3/33 11/33 Scarsi 85% 0.15 [0.06-0.37] death 122 (n) 140 (n) Sandhu 42% 0.58 [0.40-0.85] death 16/34 63/78 Rodriguez-Nava 6% 0.94 [0.61-1.47] death 16/52 85/261 Tardif (DB RCT) 44% 0.56 [0.19-1.67] death 5/2,235 9/2,253 Tau2 = 0.26; I2 = 63.0% Late treatment 56% 0.44 [0.26-0.76] 41/2,567 174/2,851 56% improvement All studies 56% 0.44 [0.26-0.76] 41/2,567 174/2,851 56% improvement 7 colchicine COVID-19 peer reviewed trials c19colchicine.com Oct 16, 2021 Tau2 = 0.26; I2 = 63.0%; Z = 2.97 Effect extraction pre-specified Favors colchicine Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Deftereos (RCT) 77% 0.23 [0.03-1.97] death 1/55 4/50 Improvement, RR [CI] Treatment Control Deftereos (RCT) 82% 0.18 [0.02-1.50] ventilation 1/55 5/50 Deftereos (RCT) 87% 0.13 [0.01-0.97] progression 1/55 7/50 Lopes (DB RCT) 80% 0.20 [0.01-4.03] death 0/36 2/36 Lopes (DB RCT) 50% 0.50 [0.10-2.56] ICU 2/36 4/36 Brunetti (PSM) 73% 0.27 [0.08-0.89] death 3/33 11/33 Brunetti (PSM) 73% 0.27 [0.08-0.89] no disch. 3/33 11/33 Scarsi 85% 0.15 [0.06-0.37] death 122 (n) 140 (n) Salehzadeh (RCT) 23% 0.77 [0.66-0.90] hosp. time 50 (n) 50 (n) Pinzón 35% 0.65 [0.34-1.21] death 14/145 23/156 Sandhu 42% 0.58 [0.40-0.85] death 16/34 63/78 Sandhu 53% 0.47 [0.33-0.67] ventilation 16/34 68/68 Sandhu 42% 0.58 [0.40-0.85] no disch. 16/34 63/78 Rodriguez-Nava 6% 0.94 [0.61-1.47] death 16/52 85/261 Tardif (DB RCT) 44% 0.56 [0.19-1.67] death 5/2,235 9/2,253 Tardif (DB RCT) 47% 0.53 [0.25-1.09] ventilation 11/2,235 21/2,253 Tardif (DB RCT) 20% 0.80 [0.61-1.03] hosp. 101/2,235 128/2,253 Horby (RCT) -1% 1.01 [0.93-1.10] death 1,173/5,610 1,190/5,730 Gaitán-Dua.. (RCT) 19% 0.81 [0.48-1.35] death 22/153 28/161 CT1 Gaitán-Dua.. (RCT) 15% 0.85 [0.68-1.06] ventilation 27/136 27/140 CT1 Gaitán-Dua.. (RCT) 1% 0.99 [0.56-1.74] ICU 19/113 18/114 CT1 Dorward (RCT) -30% 1.30 [0.42-3.84] hosp./death 6/156 4/133 Dorward (RCT) 22% 0.78 [0.30-1.73] hosp./death 6/156 119/1,145 Dorward (RCT) 6% 0.94 [0.79-1.11] progression 102/156 83/120 Dorward (RCT) 6% 0.94 [0.72-1.24] no recov. 156 (n) 133 (n) colchicine COVID-19 outcomes c19colchicine.com Oct 16, 2021 Favors colchicine Favors control
Please send us corrections, updates, or comments.
Vaccines and treatments are both extremely valuable and complementary. All
practical, effective, and safe means should be used. Elimination of COVID-19
is a race against viral evolution. No treatment, vaccine, or intervention is
100% available and effective for all current and future variants. Denying the
efficacy of any method increases the risk of COVID-19 becoming endemic; and
increases mortality, morbidity, and collateral damage. We do not provide
medical advice. Before taking any medication, consult a qualified physician
who can provide personalized advice and details of risks and benefits based
on your medical history and situation. Treatment protocols for physicians are
available from the FLCCC .
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.
Submit
